Total for the last 12 months
number of access : ?
number of downloads : ?
ID 118470
Author
Kyou, Yoshitaka Kitasato University
Yasui‑Furukori, Norio Dokkyo Medical University
Hasegawa, Naomi National Center of Neurology and Psychiatry
Ide, Kenta National Center of Neurology and Psychiatry|University of Occupational and Environmental Health
Ichihashi, Kayo University of Tokyo
Hashimoto, Naoki Hokkaido University
Hori, Hikaru Fukuoka University
Shimizu, Yoshihito Kanazawa Medical University
Imamura, Yayoi Kyorin University
Muraoka, Hiroyuki Kitasato University
Iida, Hitoshi Fukuoka University
Ohi, Kazutaka Gifu University
Yasuda, Yuka National Center of Neurology and Psychiatry|Life Grow Brilliant Mental Clinic
Ogasawara, Kazuyoshi Nagoya University
Tsuboi, Takashi Kyorin University
Ochi, Shinichiro Ehime University
Kodaka, Fumitoshi The Jikei University School of Medicine
Furihata, Ryuji Kyoto University
Onitsuka, Toshiaki Kyushu University
Makinodan, Manabu Nara Medical University
Komatsu, Hiroshi Tohoku University
Takeshima, Masahiro Akita University
Kubota, Chika National Center of Neurology and Psychiatry
Hishimoto, Akitoyo Yokohama City University
Atake, Kiyokazu Nippon Telegraph and Telephone West Corporation
Yamagata, Hirotaka Yamaguchi University
Kido, Mikio Kido Clinic|University of Toyama
Nagasawa, Tatsuya Kanazawa Medical University
Usami, Masahide Kohnodai Hospital
Kishimoto, Taishiro Keio University
Kikuchi, Saya Tohoku University
Matsumoto, Junya National Center of Neurology and Psychiatry
Miura, Kenichiro National Center of Neurology and Psychiatry
Yamada, Hisashi Hyogo Medical University|National Center of Neurology and Psychiatry
Watanabe, Koichiro Kyorin University
Inada, Ken Kitasato University
Hashimoto, Ryota National Center of Neurology and Psychiatry
Keywords
Depression
EGUIDE
Pro re nata
Psychotropic
Schizophrenia
Content Type
Journal Article
Description
Background: Several guidelines recommend monotherapy in pharmacotherapy for schizophrenia and major depressive disorder. The content of regular prescriptions has been reported in several studies, but not enough research has been conducted on the content of pharmacotherapy, including pro re nata (PRN) medications. The purpose of this study was to evaluate the content of pharmacotherapy, including PRN medications, and to clarify the relationship with regular prescriptions.
Methods: We used data from the “Effectiveness of Guidelines for Dissemination And Education in psychiatric treatment” (EGUIDE) project to investigate the presence or absence of PRN psychotropic medications at discharge for each drug category. We compared the PRN psychotropic prescription ratio at discharge by diagnosis for each drug category. The antipsychotic monotherapy ratio and no prescription ratio of other psychotropics for schizophrenia at discharge and the antidepressant monotherapy ratio and no prescription ratio of other psychotropics for major depressive disorder at discharge were calculated for each regular prescription, including PRN psychotropic medications, as quality indicators (QIs). Spearman’s rank correlation test was performed for QI values of regular prescriptions and the QI ratio between regular prescriptions and prescriptions including PRN medications for each diagnosis.
Results: The PRN psychotropic prescription ratio at discharge was 28.7% for schizophrenia and 30.4% for major depressive disorder, with no significant differences by diagnosis. The prescription ratios of PRN antipsychotic medications and PRN antiparkinsonian medications were significantly higher for schizophrenia. The prescription ratios of PRN anxiolytic and hypnotic and PRN antidepressant medications were significantly higher for patients with major depressive disorder. For both schizophrenia and major depressive disorder, the QI was lower for discharge prescriptions, including PRN medications, than for regular prescriptions. QI values for regular prescriptions and the QI ratio were positively correlated.
Conclusions: Considering PRN psychotropic medications, the monotherapy ratio and no prescription ratio of other psychotropics at discharge decreased in pharmacotherapy for schizophrenia and major depressive disorder. A higher ratio of monotherapy and no prescription of other psychotropics on regular prescriptions may result in less concomitant use of PRN psychotropic medications. Further studies are needed to optimize PRN psychotropic prescriptions.
Journal Title
Annals of General Psychiatry
ISSN
1744859X
Publisher
BMC|Springer Nature
Volume
21
Start Page
52
Published Date
2022-12-26
Remark
著者英表記誤記あり (誤)Ryota Hahimoto→(正)Ryota Hashimoto
Rights
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
EDB ID
DOI (Published Version)
URL ( Publisher's Version )
FullText File
language
eng
TextVersion
Publisher
departments
Medical Sciences